title: Pregnancy outcomes in a recurrent preterm birth prevention clinic.
abstract: OBJECTIVE
  We sought to compare rates of recurrent spontaneous preterm birth (PTB) and neonatal morbidity between women enrolled in a recurrent PTB prevention clinic compared to those receiving usual care.
  
  
  METHODS
  This was a retrospective cohort study of women with a single, nonanomalous fetus and ≥1 spontaneous PTB <35 weeks. Women enrolled in a recurrent PTB prevention clinic were compared to those receiving usual care. The recurrent PTB prevention clinic was consultative and included 3 standardized visits. Usual-care patients were treated by their primary provider. The primary outcome was recurrent spontaneous PTB <37 weeks.
  
  
  RESULTS
  Seventy recurrent PTB prevention clinic and 153 usual-care patients were included. Both groups had similar pregnancy histories. Recurrent PTB prevention clinic patients had increased utilization of resources, had lower rates of recurrent spontaneous PTB (48.6% vs 63.4%, P = .04), delivered later (mean 36.1 vs 34.9 weeks, P = .02), and had lower rates of composite major neonatal morbidity (5.7% vs 16.3%, P = .03).
  
  
  CONCLUSIONS
  Women referred to a consultative recurrent PTB prevention clinic had reduced rates of recurrent spontaneous prematurity and major neonatal morbidity.
authors.affiliation: Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology, University of Utah School of Medicine, Salt Lake City, UT 84132, USA. Tracy.manuck@hsc.utah.edu
authors.forename: Tracy A
authors.initials: TA
authors.lastname: Manuck
authors.forename: Erick
authors.initials: E
authors.lastname: Henry
authors.forename: Jonathan
authors.initials: J
authors.lastname: Gibson
authors.forename: Michael W
authors.initials: MW
authors.lastname: Varner
authors.forename: T Flint
authors.initials: TF
authors.lastname: Porter
authors.forename: G Marc
authors.initials: GM
authors.lastname: Jackson
authors.forename: M Sean
authors.initials: MS
authors.lastname: Esplin
mesh_terms: D019326:17-alpha-Hydroxyprogesterone / Q000627:therapeutic use; D000328:Adult; D054791:Cervical Length Measurement; D002985:Clinical Protocols; D015331:Cohort Studies; D005260:Female; D058869:Gynecological Examination; D006801:Humans; D008297:Male; D009543:Nifedipine / Q000627:therapeutic use; D010044:Outpatient Clinics, Hospital; D011247:Pregnancy; D011256:Pregnancy Outcome; D047928:Premature Birth / Q000517:prevention & control*; D012189:Retrospective Studies; D055502:Secondary Prevention; D015149:Tocolytic Agents / Q000627:therapeutic use; D016482:Urinalysis; D014589:Utah
chemical_list: D015149:Tocolytic Agents; D019326:17-alpha-Hydroxyprogesterone; D009543:Nifedipine